| Date | Title | Description |
| 03.04.2026 | GLP-1 Revolution: Novo Nordisk Innovates Pricing, Expands Health Impact | Novo Nordisk aggressively reshapes the GLP-1 landscape. It launches multi-month Wegovy subscriptions in the U.S., ensuring predictable pricing and bolstering patient adherence against Eli Lilly's market dominance. Concurrently, the UK's NIC... |
| 31.03.2026 | Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly | Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug products that aims to ensure cash-paying patients pay lower, “predictable” monthly prices.
Eligible patients can choose between three-, six- or 12-month su... |
| 11.01.2026 | Oral Wegovy Transforms U.S. Obesity Treatment, Boosting Access | Novo Nordisk's oral Wegovy pill has launched in the U.S., revolutionizing obesity treatment. This daily GLP-1 medication offers a more accessible, needle-free alternative. Patients can find it through Amazon Pharmacy, major retailers, and t... |
| 09.01.2026 | Amazon Pharmacy starts offering Novo Nordisk’s Wegovy weight loss pill | Amazon said it now offers Novo Nordisk’s Wegovy weight loss pill through its digital pharmacy service.
Novo Nordisk began rolling out its first-ever GLP-1 pill in the U.S. earlier this week.
Eligible customers with insurance can pay as litt... |
| 05.01.2026 | First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. | American patients can now receive the first-ever GLP-1 pill for weight loss from Novo Nordisk, marking a new chapter of obesity treatment in the U.S.
The cash prices for the drug, called the Wegovy pill, are among the lowest on the market, ... |
| 04.11.2025 | LifeMD Sells WorkSimpli Stake for $65M to Become Pure-Play Virtual Healthcare Company | What You Should Know:
– LifeMD, Inc., a provider of virtual healthcare services and pharmacy, today announced the sale of its majority ownership interest in WorkSimpli Software LLC in a transaction valuing WorkSimpli at an enterprise value ... |
| 30.10.2025 | Closing the Women’s Health Gap: LifeMD Taps “The Hormone Guru” for Virtual Care Initiative | Despite growing awareness around women’s health issues, significant gaps remain in diagnosis and treatment access across multiple conditions.
x
Please enable JavaScript
x
Please enable JavaScript
Halle Bailey's Breakup: The Lessons For ALL ... |
| 18.08.2025 | Novo Nordisk offers Ozempic at $499 per month to eligible US cash-paying customers | Novo Nordisk offers Ozempic at $499 per month to eligible US cash-paying customers
By Sneha S KAugust 18, 20256:00 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Pens for the diabetes drug Ozem... |
| 05.08.2025 | Former X CEO Yaccarino takes helm at GLP-1 focused telehealth firm eMed | Former X CEO Yaccarino takes helm at GLP-1 focused telehealth firm eMed
By ReutersAugust 5, 20253:17 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Linda Yaccarino, then CEO of X Corp., respond... |
| 22.05.2025 | LifeMD Launches $299 Introductory Wegovy® Bundle for Self-Pay Patients in Collaboration with Novo Nordisk | What You Should Know:
– LifeMD, Inc., a provider of virtual primary care services announced a limited-time $299 introductory bundle for new self-pay patients prescribed Wegovy® (semaglutide).
– The comprehensive package includes both the GL... |
| 07.05.2025 | Novo Nordisk shares pop as drugmaker sees copycat Wegovy sales easing in 2025 | Shares of Novo Nordisk climbed on Wednesday after it said that sales of its blockbuster Wegovy weight loss drug were seen improving in the second half of the year as copycat compounded drugs are phased out.
The Danish pharmaceutical giant r... |
| 07.05.2025 | StackAI Raises $16M in Series A Funding | StackAI, a San Francisco, CA-based platform provider that enables enterprises to create custom AI Agents, raised $16M in Series A funding.
The round was led by Lobby VC, with participation from LifeX Ventures, Guillermo Rauch (CEO of Vercel... |
| 28.04.2025 | LifeMD Enters Women’s Health Market Through Acquisition of Optimal Human Health MD Assets | What You Should Know:
– LifeMD, a provider of virtual primary care services, today announced the strategic acquisition of key assets from Optimal Human Health MD (“Optimal”), a nationwide virtual care provider specializing in women’s health... |
| 13.02.2025 | Health-E Commerce® launches new telehealth collaboration with LifeMD™ to make weight management medications accessible through FSA Store® and HSA Store® | FSA and HSA users now have access to LifeMD weight management services through FSA Store and HSA Store.
Individuals enrolled in flexible spending accounts (FSAs) and health savings accounts (HSAs) can receive 50% off provider visits and tre... |
| 21.12.2024 | L.A. Law Group Investigates LifeMD for Alleged Fraudulent Cancellation Practices; Seeks Individuals Impacted by Unlawful Subscription Tactics | LA Lawyer Logo
Consumer rights firm L.A. Law Group investigates LifeMD's alleged deceptive subscription tactics, seeking individuals impacted by cancellation hurdles.
LOS ANGELES, Dec. 21, 2024 /PRNewswire-PRWeb/ -- L.A. Law Group, a consum... |
| 22.05.2024 | The framework for lasting weight loss success | (BPT) - Everyone is buzzing about prescription GLP-1 medications like Ozempic and Wegovy for weight loss — and rightfully so. GLP-1s (more formally known as glucagon-like peptide 1 agonists) represent an enormous step forward in ending the ... |
| 02.05.2024 | LifeMD Integrates with Withings: GLP-1 Weight Loss with In-Home Monitoring | What You Should Know:
– LifeMD, Inc.® (Nasdaq: LFMD), a leading provider of virtual primary care services, and Withings Health Solutions, a leader in digital health technology, announce a new strategic partnership designed to revolutionize ... |
| 21.03.2024 | 5 health benefits of taking GLP-1 medication | (BPT) - GLP-1 medications like Ozempic, Wegovy, and Mounjaro are getting major press for their ability to help people slim down. But that’s just the half of it. These groundbreaking drugs, which mimic a hormone called glucagon-like peptide-... |
| 11.03.2024 | LifeMD Reports Fourth Quarter 2023 Results | - |
| 11.03.2024 | LifeMD Reports Fourth Quarter 2023 Results | Fourth quarter revenue increased 60% year-over-year to $44.9 million with Telehealth revenues increasing 90% versus the year-ago period.
Adjusted EPS of $0.15 per share compared with $0.02 in the year-ago period.
Consolidated adjusted EBITD... |
| 28.06.2023 | LifeMD Launches GLP-1 Weight Management Program | Virtual primary care company LifeMD is jumping on the glucagon-like peptide 1 (GLP-1) train through its launch of a weight management program, the company announced Tuesday.
New York City-based LifeMD is a direct-to-consumer company and its... |
| 19.05.2023 | The Future of Primary Care | Future of Primary Care
Revolutionizing Primary Care: A Deep Dive into Innovative Solutions and Investment Opportunities
Primary care is integral to the U.S. healthcare system, accounting for 50% of annual medical visits. However, with only ... |
| 25.10.2021 | Y42, a full-stack data platform for non-coders, raises $31M | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
Y42, a platform that enables anyone in a company ... |
| 25.10.2021 | Y42, a full-stack data platform for non-coders, raises $31M | Y42, a platform that enables anyone in a company to build an enterprise-grade data stack with minimal coding, has raised $31 million in a series A round of funding led by Atomico and Insight Partners.
The value of combining data from across... |
| 25.10.2021 | Data platform Y42 raises $31M | Berlin-based low-code data platform Y42 today announced that it has raised a $31 million Series A funding round co-led by Atomico and Insight Partners. La Famiglia, which led the company’s seed round, and Data Community Fund also participat... |
| 12.08.2021 | LifeMD Reports Q2 2021 Revenue Up 145% to Record $22.3 Million, Driven by Reduced Acquisition Costs and Strong Retention | New patient Customer Acquisition Cost (CAC) decreased 8% sequentially, while new patient acquisitions per day for comparable brands increased 11%
Revenue increased to a record $22.3 million, up 145% from the same year-ago period93% of Q2 20... |
| 03.06.2021 | LIFEMD, INC.
LifeMD, Inc. Closes $15 Million Debt Financing with B. Riley Principal Investments | LifeMD, Inc. announced that it has successfully closed a $15 million debt financing with B. Riley Principal Investments. Additional liquidity significantly strengthens balance sheet and supports the companys aggressive growth plan through ... |
| 13.05.2021 | LIFEMD, INC.
LifeMD : Reports Q1 2021 Revenue up 323% to Record $18.2M, Raises Full Year Revenue Guidance to $90-$100M | 92% of Q1 2021 revenue was generated by subscriptions, up from 75% in Q1 2020
Total patients and customers served nationwide surpassed 320,000
Gross Margins of 82%, up 13% from the same year-ago period
Total Telehealth Order volume grew by ... |
| 19.04.2021 | LIFEMD, INC.
LifeMD Announces Expected Record Revenue of $18.2M for Q1'21, Up 323% Vs. Q1'20, Due to Growth in Subscriptions and Patient Acquisition | NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (“the Company”) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced expected record revenue of $18.2M for Q1’21. The Company had previously guided towards... |
| 22.03.2021 | No-code business intelligence service y42 raises $2.9M seed round | Berlin-based y42 (formerly known as Datos Intelligence), a data warehouse-centric business intelligence service that promises to give businesses access to an enterprise-level data stack that’s as simple to use as a spreadsheet, today announ... |
